Kinarus KIN001 Shows Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5

 Kinarus Therapeutics’KIN001Shows Strong Antiviral ActivityAgainst SARS-CoV-2Omicron Subvariants BA.2 and BA.5

• Researchersat Friedrich-Alexander-Universität Erlangen-Nürnberg and Kinarus report newantiviral data of KIN001 against SARS-CoV-2Omicron BA.2 and BA.5 subvariants
• KINFAST Phase 2 trial of KIN001 in ambulatory COVID-19 patients is actively recruiting

https://www.biospace.com/article/releases/-kinarus-therapeutics-kin001-shows-strong-antiviral-activity-against-sars-cov-2-omicron-subvariants-ba-2-and-ba-5/